USPTO serial 87736062
EPI X
Reviewed by CopyMark Law Group
Status 605
- Filing date
- Status date
- Registration date
- —
- Examiner
- BUTTON, JENNIFER JO
- Law office
- GENERIC WEB UPDATE
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with EPI X?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Göteborg, SE
Göteborg, SE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Margarita Wallach
MARGARITA WALLACH MCCARTER & ENGLISH LLPWORLDWIDE PLAZA, 825 EIGHTH AVE., 31ST FNEW YORK, NY 10019UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biologically compatible polymers, namely, hydrogels used to manufacture polymeric networks used in the manufacture of engineered living tissue for medical, scientific and non-scientific purposes; Media for cell culture for use in the biotechnological industry; Media for cell culture for use in non-medical research laboratories; Biological preparation for use in cell cultures other than for medical or veterinary use; Engineered biological tissues and tissue arrays, namely, human and animal organ, connective, epithelial, muscular, and nervous tissues and tissue arrays, for use in scientific and medical research; Biologically compatible materials, namely, hydrogels used to create polymeric networks used in the manufacture of living tissue; Proteins in raw material form for scientific and medical research | ABANDONED | — |
| 005 | Pharmaceutical preparations for use in the field of 3D bio-printing of tissues and organs; Preparations based on cellulous nano-fibrils for use in the 3D bio-printing of tissues and organs; Tissue-regenerative pharmaceutical preparations; Cells for medical use; Human allograft tissue; Living cells for medical use; Implants of living tissues for guided tissue regeneration; Implants comprising living tissue; Implantable materials of living tissue for use in guided tissue regeneration; Skin grafts; Surgical implants comprised of living tissues; Surgical implants of living tissues grown from stem cells; Transdermal patches for use to create skin for prosthetic limbs and for skin grafts; Living tissues for transplant; Engineered biological tissues and organs, namely, human and animal cardiovascular, pulmonary, digestive, hepatobiliary, urological, renal, endocrine, connective, epithelial, muscular, and nervous tissue and organs, for medical purposes; Biological molecules to assist in the development of tissue; Haemostatic gel matrix preparations for treating wounds; Natural biomaterials for augmentation of bone, blood and tissue for medical purposes; Pharmaceutical products for tissue regeneration, for tissue repair, for tissue treatment, whether relating to human or animal tissue; Pharmaceutical preparations for the treatment of bone diseases, for cartilaginous diseases, for vascular diseases, for neuronal degeneration, for degeneration of tendons and ligaments, for retinal degeneration, for renal degeneration, degeneration of soft tissue, for diseases with abnormal cell proliferation; Natural biomaterials for bone filling; Natural biomaterials for filling cartilage; Biological tissue cultures for medical use; Biological tissue cultures for medical purposes; Biological tissue grafts; Biological bone and skin tissues impregnated with lines of oxygen for tissue engineering applications to increase cell survival in tissue intended for subsequent implantation; Gene therapy products, namely, genetically engineered tissues for transplant purposes; Implantable scaffolds comprising living tissue for maintaining tissue contour; Implants comprising living tissue; Natural biomaterials for augmentation of bone and tissue for medical purposes | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 6, 2019 | MAB5 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION | — |
| May 6, 2019 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| May 2, 2019 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Feb 1, 2019 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jan 8, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 8, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 19, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 2, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 13, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 13, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 9, 2018 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Nov 5, 2018 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 1, 2018 | ALIE | ASSIGNED TO LIE | — |
| Apr 14, 2018 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 14, 2018 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 14, 2018 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Apr 6, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 12, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 30, 2017 | NWAP | NEW APPLICATION ENTERED | — |